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Abstract
In the past decade we have learned a lot about the
pathophysiology of septic shock. A lot of experimental research
has been performed in vitro and in vivo, showing that hemofiltration
can improve hemodynamics and survival. With modern machines,
hemofiltration is becoming a sepsis treatment in patients.
Since continuous haemofiltration (HF) was first described by
Kramer as a new form of renal replacement therapy [1], it has
undergone many changes, making it a widely accepted
treatment modality for acute renal failure in critically ill
patients. Concomitantly, new insights into the pathogenesis
of severe sepsis and septic shock recently led to new forms
of immunomodulatory therapy for septic shock. A number of
clinical trials investigating the effect of antiendotoxin or
anticytokine interventions were unable to demonstrate a
consistent improvement in survival of patients with sepsis or
septic shock. Another possible immunotherapy is removal of
various inflammatory substances, including endotoxin,
cytokines, oxygen-free radicals and arachidonic acid
metabolites, by HF.
In this issue of Critical Care Ratanarat and coworkers [2]
report the results of an observational study in patients with
septic shock who were treated with ‘pulse high volume
hemofiltration’. Ratanarat and colleagues utilized a HF rate of
85 ml/kg per hour for 6–8 hours, followed by a more
conventional rate of 35 ml/kg per hour. It is indeed now
accepted that 35 ml/kg per hour should be used in patients
with acute renal failure who are treated with HF [3].
Bearing in mind that removal of the so-called ‘middle
molecules’ is a convective process, Grootendorst opted to
apply much higher volumes of ultrafiltration (UF). Grooten-
dorst and coworkers [4] introduced the concept of high-
volume haemofiltration (HVHF) in a pig endotoxin model, in
which they demonstrated improvement in haemodynamics in
the study animals as compared with controls. Moreover,
infusion of the ultrafiltrate from the endotoxic animals into
healthy ones induced the same symptoms as in the endotoxic
group [5]. In another study [6] the same group examined a
bowel ischaemia–reperfusion model. HVHF started before
the mesenteric artery was clamped significantly diminished
bowel damage and prevented haemodynamic deterioration.
These studies established that convective removal of septic
mediators can be performed when sufficiently high UF rates
are applied.
Several studies have confirmed these findings. In all of these
a similar improvement in haemodynamics was found, and
some even reported an increase in survival [7-9]. In one study
[8], different UF rates were compared in a clinically
representative model of severe pancreatitis in pigs. HVHF at
a rate of 100 ml/kg per hour was better than low-volume HF.
Frequent filter change, allowing more adsorption of cytokines,
was also better than no change. These data were confirmed
in a very recent study conducted in the same model [10].
Several studies have examined the effects of HVHF in
patients. In one study [11] HVHF was performed during
cardiopulmonary bypass in children undergoing cardiac
surgery, which resulted in a blunted inflammatory response,
reduction in postoperative blood loss and improved
oxygenation. In a prospective cohort analysis [12], in which
306 critically ill patients with acute renal failure were treated
with an UF rate of 3.8 l/hour, the observed survival rates were
significantly better than predicted. In a small trial of 11
patients with shock and multiple organ dysfunction syndrome
[13] the authors compared an UF rate of 1 l/hour with
6 l/hour using a crossover design. HVHF resulted in a
significant reduction in vasopressor requirements and a
greater reduction in levels of complement 3 and 5. In another
Commentary
High-volume hemofiltration in septic shock
Peter Rogiers
Intensive Care Unit, Middelheim General Hospital, Ziekenhuisnetwerk Antwerpen, Antwerp, Belgium
Corresponding author: Peter Rogiers, peter.rogiers@zna.be
Published online: 2 June 2005 Critical Care 2005, 9:329-330 (DOI 10.1186/cc3734)
This article is online at http://ccforum.com/content/9/4/329
© 2005 BioMed Central Ltd
See related research article by Ratanarat et al., in this issue [http://ccforum.com/content/9/4/R294]330
Critical Care    August 2005 Vol 9 No 4 Rogiers
study conducted in 20 patients with refractory septic shock,
Honoré and coworkers [14] gave a 4-hour treatment with
HVHF, followed by conventional continuous venovenous
haemofiltration. Eleven patients responded to the treatment
with increases in cardiac index, venous oxygen saturation and
arterial pH, and a decrease in norepinephrine requirement. Of
these responders, nine out of eleven survived to 28 days; all
of the nonresponders died.
Ratanarat and coworkers [2] show that HVHF, following its
birth as a theoretical concept and subsequent experimental
research in animals, is progressing toward the bedside of our
critically ill patients. This modality is feasible with modern HF
machines and the available fluids, and can be performed
without major side effects.
It is increasingly accepted that the ‘renal dose’ of HF is not
the same as the ‘septic dose’. We must define those patient
populations that may require this form of treatment and those
that can be treated with more conventional renal replacement
therapy. Despite initial scepticism, we are beginning to learn
that HF for severe sepsis and septic shock is more than
bloodletting, 21st century style.
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